LaFleur & Godfrey LLC Buys 440 Shares of Danaher Co. (NYSE:DHR)

LaFleur & Godfrey LLC grew its stake in shares of Danaher Co. (NYSE:DHR) by 1.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 29,855 shares of the conglomerate’s stock after purchasing an additional 440 shares during the quarter. LaFleur & Godfrey LLC’s holdings in Danaher were worth $6,853,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Fort Pitt Capital Group LLC increased its stake in shares of Danaher by 3.2% during the third quarter. Fort Pitt Capital Group LLC now owns 238,092 shares of the conglomerate’s stock valued at $66,194,000 after buying an additional 7,421 shares during the period. Good Life Advisors LLC purchased a new position in Danaher during the 3rd quarter valued at $217,000. ORG Partners LLC raised its holdings in Danaher by 1,212.8% in the 4th quarter. ORG Partners LLC now owns 2,770 shares of the conglomerate’s stock worth $636,000 after purchasing an additional 2,559 shares in the last quarter. Harvest Portfolios Group Inc. lifted its position in shares of Danaher by 1.2% in the 3rd quarter. Harvest Portfolios Group Inc. now owns 202,263 shares of the conglomerate’s stock worth $56,233,000 after purchasing an additional 2,465 shares during the period. Finally, Stifel Financial Corp boosted its stake in shares of Danaher by 1.3% during the 3rd quarter. Stifel Financial Corp now owns 847,348 shares of the conglomerate’s stock valued at $235,583,000 after purchasing an additional 11,216 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

Danaher Trading Down 1.4 %

Danaher stock opened at $238.41 on Monday. Danaher Co. has a one year low of $222.53 and a one year high of $281.70. The business’s fifty day moving average is $234.85 and its 200 day moving average is $253.42. The stock has a market capitalization of $172.20 billion, a PE ratio of 45.50, a price-to-earnings-growth ratio of 4.23 and a beta of 0.83. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. The firm had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.59 billion. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The business’s revenue for the quarter was up 3.1% on a year-over-year basis. During the same period in the previous year, the business posted $2.02 earnings per share. On average, sell-side analysts predict that Danaher Co. will post 7.49 EPS for the current year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be issued a dividend of $0.27 per share. The ex-dividend date is Friday, December 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.45%. Danaher’s payout ratio is 20.61%.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on DHR. Royal Bank of Canada decreased their price target on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating for the company in a research note on Wednesday, October 23rd. Evercore ISI raised their target price on Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Citigroup reduced their price target on Danaher from $305.00 to $285.00 and set a “buy” rating on the stock in a research note on Monday, January 6th. Bank of America raised Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price objective for the company in a research report on Friday, December 13th. Finally, Guggenheim started coverage on shares of Danaher in a research report on Thursday, December 19th. They issued a “buy” rating and a $275.00 target price on the stock. Six analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $286.80.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.